DOCSLIB.ORG

Publications 2016 – 2018

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Publications 2016 – 2018 PUBLICATIONS 2016 – 2018 (as reported in PubMed, to be updated annually) DEPARTMENT OF MEDICINE DIVISION OF ALLERGY, ASTHMA and IMMUNOLOGY Kevin Cook, MD Improvement in Asthma Control Using a Minimally Burdensome and Proactive Smartphone Application. Cook KA, Modena BD, Simon RA. J Allergy Clin Immunol Pract. 2016 Jul-Aug;4(4):730-737.e1. doi: 10.1016/j.jaip.2016.03.005. Epub 2016 Apr 20. PMID:27107690 Rapid Aspirin Challenge in Patients with Aspirin Allergy and Acute Coronary Syndromes. Cook KA, White AA. Curr Allergy Asthma Rep. 2016 Feb;16(2):11. doi: 10.1007/s11882-015-0593-2. Review. PMID:26758864 Increased risk of systemic reactions extends beyond completion of rush immunotherapy. Cook KA, Kelso JM, White AA. J Allergy Clin Immunol Pract. 2017 Nov - Dec;5(6):1773-1775. doi: 10.1016/j.jaip.2017.04.015. Epub 2017 May 11. No abstract available. PMID: 28506424 Use of a composite symptom score during challenge in patients with suspected aspirin-exacerbated respiratory disease. Cook KA, Modena BD, Wineinger NE, Woessner KM, Simon RA, White AA. Ann Allergy Asthma Immunol. 2017 May;118(5):597-602. doi: 10.1016/j.anai.2017.02.016. PMID: 28477789 Half of systemic reactions to allergen immunotherapy are delayed, majority require treatment with epinephrine. Cook KA, Ford CM, Leyvas EA, Waalen J, White AA. J Allergy Clin Immunol Pract. 2017 Sep - Oct;5(5):1415-1417. doi: 10.1016/j.jaip.2017.03.025. Epub 2017 Apr 25. No abstract available. PMID:28454684 A 30-year-old woman with chronic hives, intermittent fevers, and joint pain. Cook KA, Lynch MT, Weis PJ, White AA. Allergy Asthma Proc. 2017 May 1;38(3):231-235. doi: 10.2500/aap.2017.38.4039. PMID:28441994 Surgery-Related Contact Dermatitis: A Review of Potential Irritants and Allergens. Cook KA, Kelso JM. J Allergy Clin Immunol Pract. 2017 Sep - Oct;5(5):1234-1240. doi: 10.1016/j.jaip.2017.03.001. Epub 2017 Apr 7. Review. PMID: 28396114 Happy asthma: Improved asthma control with a gratitude journal. Cook KA, Woessner KM, White AA. J Allergy Clin Immunol Pract. 2018 May 3. pii: S2213-2198(18)30298-8. doi: 10.1016/j.jaip.2018.04.021. [Epub ahead of print] No abstract available. PMID: 29730452 Total: 8 John Kelso, MD Vaccine Reactions. Reddy AP, Kelso JM. J Allergy Clin Immunol Pract. 2017 Sep - Oct;5(5):1463-1464. doi: 10.1016/j.jaip.2017.06.011. No abstract available. PMID: 28888256 Increased risk of systemic reactions extends beyond completion of rush immunotherapy. Cook KA, Kelso JM, White AA. J Allergy Clin Immunol Pract. 2017 May 11. pii: S2213-2198(17)30260-X. doi: 10.1016/j.jaip.2017.04.015. PMID: 28506424 Surgery-Related Contact Dermatitis: A Review of Potential Irritants and Allergens. Cook KA, Kelso JM. J Allergy Clin Immunol Pract. 2017 Sep - Oct;5(5):1234-1240. doi: 10.1016/j.jaip.2017.03.001. Epub 2017 Apr 7. PMID: 28396114 Omalizumab anaphylaxis occurring outside the recommended observation times. Kelso JM. J Allergy Clin Immunol. 2017 May;139(5):1718. doi: 10.1016/j.jaci.2016.12.977. Epub 2017 Mar 6. No abstract available. PMID: 28268017 International Consensus (ICON): allergic reactions to vaccines. Dreskin SC, Halsey NA, Kelso JM, Wood RA, Hummell DS, Edwards KM, Caubet JC, Engler RJ, Gold MS, Ponvert C, Demoly P, Sanchez-Borges M, Muraro A, Li JT, Rottem M, Rosenwasser LJ. World Allergy Organ J. 2016 Sep 16;9(1):32. doi: 10.1186/s40413-016-0120-5. eCollection 2016. PMID: 27679682 Do Written Asthma Action Plans Improve Outcomes? Kelso JM. Pediatr Allergy Immunol Pulmonol. 2016 Mar 1;29(1):2-5. Review. PMID: 27158550 Provocation Challenges to Evaluate Amoxicillin Allergy in Children. Kelso JM. JAMA Pediatr. 2016 Jun 6;170(6):e160282. doi: 10.1001/jamapediatrics.2016.0282. Epub 2016 Jun 6. No abstract available. PMID: 27043299 Following total IgE concentration in patients with allergic bronchopulmonary aspergillosis on omalizumab. Kelso JM. J Allergy Clin Immunol Pract. 2016 Mar-Apr;4(2):364-5. doi: 10.1016/j.jaip.2015.11.014. Epub 2015 Dec 24. No abstract available. PMID: 26725160 How to apply the LEAP study. Kelso JM. J Allergy Clin Immunol. 2016 Jan;137(1):332-334. doi: 10.1016/j.jaci.2015.09.042. Epub 2015 Nov 14. No abstract available. PMID: 26586035 Unproven Diagnostic Tests for Adverse Reactions to Foods. Kelso JM. J Allergy Clin Immunol Pract. 2018 Mar - Apr;6(2):362-365. doi: 10.1016/j.jaip.2017.08.021. PMID:29524991 Administration of influenza vaccines to egg allergic recipients: A practice parameter update 2017. Greenhawt M, Turner PJ, Kelso JM. Ann Allergy Asthma Immunol. 2018 Jan;120(1):49-52. doi: 10.1016/j.anai.2017.10.020. No abstract available. PMID:29273128 Food Allergy Management. Davis CM, Kelso JM. Immunol Allergy Clin North Am. 2018 Feb;38(1):53-64. doi: 10.1016/j.iac.2017.09.005. Review. PMID:29132674 TOTAL: 12 Brian Modena, MD Aspirin and Nonsteroidal Antiinflammatory Drugs Hypersensitivity and Management. Modena B, White AA, Woessner KM. Immunol Allergy Clin North Am. 2017 Nov;37(4):727-749. doi: 10.1016/j.iac.2017.07.008. Epub 2017 Sep 1. Review. PMID: 28965637 Genetic Variants and Altered Expression of non-CFTR Genes May Explain Differences in Cystic Fibrosis Severity. Modena BD. Am J Respir Crit Care Med. 2017 Sep 27. doi: 10.1164/rccm.201709-1811ED. [Epub ahead of print] No abstract available. PMID: 28954200 Use of a composite symptom score during challenge in patients with suspected aspirin-exacerbated respiratory disease. Cook KA, Modena BD, Wineinger NE, Woessner KM, Simon RA, White AA. Ann Allergy Asthma Immunol. 2017 May;118(5):597-602. doi: 10.1016/j.anai.2017.02.016. PMID: 28477789 Consistency of T2 Gene Signatures in Severe Asthma. Key to Effective Treatments or Merely the Tip of the Iceberg? Modena BD, Wenzel SE. Am J Respir Crit Care Med. 2017 Feb 15;195(4):411-412. doi: 10.1164/rccm.201609-1854ED. No abstract available. PMID: 28199166 Gene Expression Correlated with Severe Asthma Characteristics Reveals Heterogeneous Mechanisms of Severe Disease. Modena BD, Bleecker ER, Busse WW, Erzurum SC, Gaston BM, Jarjour NN, Meyers DA, Milosevic J, Tedrow JR, Wu W, Kaminski N, Wenzel SE. Am J Respir Crit Care Med. 2017 Jun 1;195(11):1449-1463. doi: 10.1164/rccm.201607- 1407OC. PMID: 27984699 Improvement in Asthma Control Using a Minimally Burdensome and Proactive Smartphone Application. Cook KA, Modena BD, Simon RA. J Allergy Clin Immunol Pract. 2016 Jul-Aug;4(4):730-737.e1. doi: 10.1016/j.jaip.2016.03.005. Epub 2016 Apr 20. PMID: 27107690 Emerging concepts: mast cell involvement in allergic diseases. Modena BD, Dazy K, White AA. Transl Res. 2016 Aug;174:98-121. doi: 10.1016/j.trsl.2016.02.011. Epub 2016 Feb 24. Review. PMID: 26976119 Gene Expression in Biopsies of Acute Rejection and Interstitial Fibrosis/Tubular Atrophy Reveals Highly Shared Mechanisms That Correlate With Worse Long-Term Outcomes. Modena BD, Kurian SM, Gaber LW, Waalen J, Su AI, Gelbart T, Mondala TS, Head SR, Papp S, Heilman R, Friedewald JJ, Flechner SM, Marsh CL, Sung RS, Shidban H, Chan L, Abecassis MM, Salomon DR. Am J Transplant. 2016 Jul;16(7):1982-98. doi: 10.1111/ajt.13728. Epub 2016 Mar 15. PMID: 26990570 Can Diet Modification Be an Effective Treatment in Aspirin-Exacerbated Respiratory Disease? Modena BD, White AA. J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):832-833. doi: 10.1016/j.jaip.2017.11.043. No abstract available. PMID: 29747986 TOTAL: 9 Jennifer Namazy, MD More Reason to Watch Your Weight During Pregnancy. Namazy JA. J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):988-989. doi: 10.1016/j.jaip.2017.05.014. No abstract available. PMID: 28689847 Allergic diseases and asthma in pregnancy, a secondary publication. Pali-Schöll I, Namazy J, Jensen-Jarolim E. World Allergy Organ J. 2017 Mar 2;10(1):10. doi: 10.1186/s40413-017-0141- 8. eCollection 2017. Review. PMID: 28286601 Pharmacological difficulties in the treatment of asthma in pregnant women. Namazy JA, Schatz M. Expert Rev Clin Pharmacol. 2017 Mar;10(3):285-292. doi: 10.1080/17512433.2017.1268914. Epub 2016 Dec 26. Review. PMID: 27927045 Antibiotics for respiratory infections during pregnancy: prevalence and risk factors. Namazy JA, Schatz M, Yang SJ, Chen W. J Allergy Clin Immunol Pract. 2016 Nov - Dec;4(6):1256-1257.e2. doi: 10.1016/j.jaip.2016.06.015. Epub 2016 Jul 21. No abstract available. PMID: 27452887 The safety of intranasal steroids during pregnancy: A good start. Namazy JA, Schatz M. J Allergy Clin Immunol. 2016 Jul;138(1):105-6. doi: 10.1016/j.jaci.2016.04.026. No abstract available. PMID: 27373328 The Treatment of Allergic Respiratory Disease During Pregnancy. Namazy J, Schatz M. J Investig Allergol Clin Immunol. 2016;26(1):1-7; quiz 2p following 7. Review. PMID: 27012010 Clinical Updates in Women's Health Care Summary: Asthma. Namazy JA, Schatz M, Dombrowski M. Obstet Gynecol. 2018 May;131(5):954. doi: 10.1097/AOG.0000000000002630. PMID: 29683908 Management of Asthma during Pregnancy: Optimizing Outcomes and Minimizing Risk. Namazy JA, Schatz M. Semin Respir Crit Care Med. 2018 Feb;39(1):29-35. doi: 10.1055/s-0037-1606216. Epub 2018 Feb 10. PMID: 29427983 TOTAL: 8 Ronald Simon, MD Effect of misoprostol on patients with aspirin-exacerbated respiratory disease undergoing aspirin challenge and desensitization. Walters KM, Simon RA, Woessner KM, Wineinger NE, White AA. Ann Allergy Asthma Immunol.
Load more

Recommended publications
  • General Items
    Essential Medicines List (EML) 2019 Application for the inclusion of imipenem/cilastatin, meropenem and amoxicillin/clavulanic acid in the WHO Model List of Essential Medicines, as reserve second-line drugs for the treatment of multidrug-resistant tuberculosis (complementary lists of anti-tuberculosis drugs for use in adults and children) General items 1. Summary statement of the proposal for inclusion, change or deletion This application concerns the updating of the forthcoming WHO Model List of Essential Medicines (EML) and WHO Model List of Essential Medicines for Children (EMLc) to include the following medicines: 1) Imipenem/cilastatin (Imp-Cln) to the main list but NOT the children’s list (it is already mentioned on both lists as an option in section 6.2.1 Beta Lactam medicines) 2) Meropenem (Mpm) to both the main and the children’s lists (it is already on the list as treatment for meningitis in section 6.2.1 Beta Lactam medicines) 3) Clavulanic acid to both the main and the children’s lists (it is already listed as amoxicillin/clavulanic acid (Amx-Clv), the only commercially available preparation of clavulanic acid, in section 6.2.1 Beta Lactam medicines) This application makes reference to amendments recommended in particular to section 6.2.4 Antituberculosis medicines in the latest editions of both the main EML (20th list) and the EMLc (6th list) released in 2017 (1),(2). On the basis of the most recent Guideline Development Group advising WHO on the revision of its guidelines for the treatment of multidrug- or rifampicin-resistant (MDR/RR-TB)(3), the applicant considers that the three agents concerned be viewed as essential medicines for these forms of TB in countries.
    [Show full text]
  • Informatorium of COVID-19 Drugs in Indonesia" Has Been Compiled and Can Be Published Amidst the COVID-19 Outbreak in Indonesia
    THE INDONESIAN FOOD AND DRUG AUTHORITY INFORMATORIUM OF COVID-19 DRUGS IN INDONESIA THE INDONESIAN FOOD AND DRUG AUTHORITY MARCH 2020 1 INFORMATORIUM OF COVID-19 DRUGS IN INDONESIA THE INDONESIAN FOOD AND DRUG AUTHORITY ISBN 978-602-415-009-9 First Edition March 2020 COPYRIGHT PROTECTED BY LAW Reproduction of this book in part or whole, in any form and by any means, mechanically or electronically, including photocopies, records, and others without written permission from the publisher. This informatorium is based on information up to the time of publication and is subject to change if there is the latest data/information 2 3 FOREWORD Our praise and gratitude for the presence of God Almighty for His blessings and gifts, "The Informatorium of COVID-19 Drugs in Indonesia" has been compiled and can be published amidst the COVID-19 outbreak in Indonesia. As we know, the infections due to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) began to plague in December 2019 in Wuhan City, Hubei Province, People's Republic of China. The disease was caused by SARS-CoV-2 infection which was later known as Coronavirus Disease 2019 (COVID-19) which in early 2020 began to spread to several countries and eventually spread to almost all countries in the world. On March 11, 2020, WHO announced COVID-19 as a global pandemic. In Indonesia, the first case was officially announced on March 2, 2020. Considering that the spread of COVID-19 has been widespread and has an impact on social, economic, defense, and public welfare aspects in Indonesia, the President of the Republic of Indonesia established the Task Force for the Acceleration of COVID- 19 Handling aiming to increase readiness and ability to prevent, detect and respond to COVID-19.
    [Show full text]
  • Clinical Pharmacology and Biopharmaceutics Review(S)
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S) CLINICAL PHARMACOLOGY REVIEW NDA: 200-327 Submission Date(s): • 30 Dec 2009 (SDN 1) • 30 Apr 2010 (SDN 14) • 04 Feb 2010 (SDN 7) • 18 Jun 2010 (SDN 19) • 23 Apr 2010 (SDN 10) • 06 Aug 2010 (SDN 31) • 29 Apr 2010 (SDN 13) • 18 Aug 2010 (SDN 34) Drug Ceftaroline Fosamil for Injection Trade Name TEFLARO™ (proposed) OCP Reviewer Aryun Kim, Pharm.D. OCP Team Leader Charles Bonapace, Pharm.D. PM Reviewer Yongheng Zhang, Ph.D. PM Team Leader Pravin Jadhav, Ph.D. OCP Division DCP4 OND division DAIOP (520) Sponsor Cerexa, Inc., Oakland, CA Relevant IND(s) IND 71,371 Submission Type; Code Original New Drug Application (New Molecular Entity), 1S Formulation; Strength(s) Sterile (b) (4) of ceftaroline fosamil and L-arginine supplied as powder in single-use, 20-cc, clear, Type I glass vials containing 600 mg or 400 mg of ceftaroline fosamil Indication For the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP) caused by designated susceptible isolates of Gram-positive and Gram-negative microorganisms Dosage and 600 mg administered every 12 hours by intravenous infusion over 1 hour Administration in patients ≥18 years of age • for 5-14 days for treatment of cSSSI • for 5-7 days for treatment of CABP 1. EXECUTIVE SUMMARY 5 1.1 Recommendations 5 1.2 Phase 4 Commitments 6 1.3 Summary of Important Clinical Pharmacology and Biopharmaceutics Findings 6 2. QUESTION-BASED REVIEW 11 2.1 General Attributes of the Drug 11 2.2 General Clinical Pharmacology 13 2.3 Intrinsic Factors 37 2.4 Extrinsic Factors 56 2.5 General Biopharmaceutics 58 2.6 Analytical Section 58 3.
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Current Use for Old Antibacterial Agents: Polymyxins, Rifamycins, and Aminoglycosides
    Current Use for Old Antibacterial Agents: Polymyxins, Rifamycins, and Aminoglycosides a, b,c Luke F. Chen, MBBS (Hons), MPH, CIC, FRACP *, Donald Kaye, MD KEYWORDS Rifaximin Pharmacokinetics Pharmacodynamics Toxicity Polymyxins Aminoglycoside Rifampin The polymyxins, rifamycins, and the aminoglycosides may be considered special use antibacterial agents. They are all old agents and are rarely considered the drugs of choice for common bacterial infections. The polymyxins are increasingly important because of the continued emergence of multidrug resistant (MDR) gram-negative organisms, such as strains of Pseudomonas aeruginosa or carbapenemase-producing Enterobacteriaceae that are susceptible to few remaining drugs. Rifampin is only considered in the context of nonmycobacterial infections where its role is limited and sometimes controversial. Rifaximin is a new enteric rifamycin that is increasingly used for gastrointestinal infections such as trav- eler’s diarrhea and Clostridium difficile infections (CDIs). This article will also review the current role of aminoglycosides in nonmycobacterial systemic infections, with an emphasis on the use of single daily administration. POLYMYXINS The polymyxins were discovered in 1947. Although there are five known polymyxin molecules, sequentially named polymyxin A through polymyxin E, only two polymyxins are available for therapeutic use: polymyxin B and polymyxin E (colistin) (Table 1). Both polymyxin B and polymyxin E are large cyclic cationic polypeptide detergents A version of this article appeared in the 23:4 issue of the Infectious Disease Clinics of North America. a Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Box 102359, Hanes House, Durham, NC 27710, USA b Department of Medicine, Drexel University College of Medicine, Philadelphia, PA 19102, USA c 1535 Sweet Briar Road, Gladwyne, PA 19035, USA * Corresponding author.
    [Show full text]
  • Treatment of Drug-Resistant Tuberculosis an Official ATS/CDC/ERS/IDSA Clinical Practice Guideline Payam Nahid, Sundari R
    AMERICAN THORACIC SOCIETY DOCUMENTS Treatment of Drug-Resistant Tuberculosis An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline Payam Nahid, Sundari R. Mase, Giovanni Battista Migliori, Giovanni Sotgiu, Graham H. Bothamley, Jan L. Brozek, Adithya Cattamanchi, J. Peter Cegielski, Lisa Chen, Charles L. Daley, Tracy L. Dalton, Raquel Duarte, Federica Fregonese, C. Robert Horsburgh, Jr., Faiz Ahmad Khan, Fayez Kheir, Zhiyi Lan, Alfred Lardizabal, Michael Lauzardo, Joan M. Mangan, Suzanne M. Marks, Lindsay McKenna, Dick Menzies, Carole D. Mitnick, Diana M. Nilsen, Farah Parvez, Charles A. Peloquin, Ann Raftery, H. Simon Schaaf, Neha S. Shah, Jeffrey R. Starke, John W. Wilson, Jonathan M. Wortham, Terence Chorba, and Barbara Seaworth; on behalf of the American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America THIS OFFICIAL CLINICAL PRACTICE GUIDELINE WAS APPROVED BY THE AMERICAN THORACIC SOCIETY, THE EUROPEAN RESPIRATORY SOCIETY, AND THE INFECTIOUS DISEASES SOCIETY OF AMERICA SEPTEMBER 2019, AND WAS CLEARED BY THE U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION SEPTEMBER 2019 Background: The American Thoracic Society, U.S. Centers for was judged to be very low, because the data came Disease Control and Prevention, European Respiratory Society, and from observational studies with significant loss to follow-up Infectious Diseases Society of America jointly sponsored this new and imbalance in background regimens between comparator practice guideline on the treatment of drug-resistant tuberculosis groups. Good practices in the management of MDR-TB are (DR-TB). The document includes recommendations on the described. On the basis of the evidence review, a clinical strategy treatment of multidrug-resistant TB (MDR-TB) as well as tool for building a treatment regimen for MDR-TB is also isoniazid-resistant but rifampin-susceptible TB.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Frequently Asked Questions on The
    Frequently asked questions on the WHO treatment guidelines for isoniazid-resistant tuberculosis Version: 24 April 2018 The advice in this document has been prepared by the Global TB Programme of the World Health Organization (WHO) and is to be read alongside the WHO treatment guidelines for isoniazid-resistant tuberculosis and its online annexes. See Further reading ​ ​ at end for additional resources. Who are the new WHO treatment guidelines for isoniazid-resistant tuberculosis intended for ? ​ ​ The WHO treatment guidelines for isoniazid-resistant tuberculosis are targeted at health care ​ professionals (doctors, nurses) and other staff involved in TB care in both low and high resource settings. The possibility of drug-resistant disease now needs to be entertained whenever treating TB patients. These guidelines provide technical detail which is helpful in making the best-informed decision in clinical practice and programme management. The answers to the frequently asked questions (FAQ) in this document intend to help implementers with common, practical issues that arise when adopting the new guidance. This document complements the WHO guidelines by elaborating further on certain aspects of ​ implementation that were beyond the scope of the guideline itself. What are the main recommendations of these new guidelines ? The new guidelines recommend that patients with confirmed isoniazid-resistant and rifampicin susceptible tuberculosis (abbreviated to Hr-TB) are treated for 6 months with a regimen composed of ​ ​ rifampicin (R), ethambutol (E), pyrazinamide (Z) and levofloxacin (Lfx). The exclusion of rifampicin resistance ahead of start of this regimen is critical. It is further recommended not to add streptomycin (S) or other injectable agents to the treatment regimen.
    [Show full text]
  • Swedres Svarm 2012
    2012 SWEDRES|SVARM Swedish Antibiotic Utilisation and Resistance in Human Medicine Swedish Veterinary Antimicrobial Resistance Monitoring 2 SWEDRES |SVARM 2012 A Report on Swedish Antibiotic Utilisation and Resistance in Human Medicine (SWEDRES) and Swedish Veterinary Antimicrobial Resistance Monitoring (SVARM) Published by: Swedish Institute for Communicable Disease Control and National Veterinary Institute Editors: Jenny Hellman and Barbro Olsson-Liljequist, Swedish Institute for Communicable Disease Control Björn Bengtsson and Christina Greko, National Veterinary Institute Addresses: The Swedish Institute for Communicable Disease Control SE-171 82 Solna, Sweden Phone: +46 (0) 8 457 23 00 Fax: +46 (0) 8 328330 E-mail: [email protected] www.smi.se The National Veterinary Institute SE-751 89 Uppsala, Sweden Phone: +46 (0) 18 67 40 00 Fax: +46 (0) 18 30 91 62 E-mail: [email protected] www.sva.se Article number 2013-101-1 ISSN 1650-6332 This title and previous SWEDRES and SVARM reports are available for downloading at www.smi.se/publikationer or www.sva.se This title can be ordered from: Smittskyddsinstitutets beställningsservice c/o Strömberg, 120 88 Stockholm Fax: +46 (0) 8 – 779 96 67 E-mail: [email protected] Department of Animal Health and Antimicrobial Strategies, National Veterinary Institute SE-751 89 Uppsala, Sweden Phone: +46 (0) 18 67 40 00 Fax: +46 (0) 18 30 91 62 E-mail: [email protected] Text and tables may be cited and reprinted only with refer- ence to this report. Images, photographs and illustrations are protected by copyright. Suggested citation: SWEDRES-SVARM 2012. Use of antimicrobials and occur- rence of antimicrobial resistance in Sweden.
    [Show full text]
  • Anti-Infective Drug Poster
    Anti-Infective Drugs Created by the Njardarson Group (The University of Arizona): Edon Vitaku, Elizabeth A. Ilardi, Daniel J. Mack, Monica A. Fallon, Erik B. Gerlach, Miyant’e Y. Newton, Angela N. Yazzie, Jón T. Njarðarson Streptozol Spectam Novocain Sulfadiazine M&B Streptomycin Chloromycetin Terramycin Tetracyn Seromycin Tubizid Illosone Furadantin Ethina Vancocin Polymyxin E Viderabin Declomycin Sulfamethizole Blephamide S.O.P. ( Sulfanilamide ) ( Spectinomycin ) ( Procaine ) ( Sulfadiazine ) ( Sulfapyridine ) ( Streptomycin ) ( Chloramphenicol ) ( Oxytetracycline ) ( Tetracycline ) ( Cycloserine ) ( Isoniazid ) ( Erythromycin ) ( Nitrofurantoin ) ( Ethionamide ) ( Vancomycin ) ( Colistin ) ( Vidarabine ) ( Demeclocycline ) ( Sulfamethizole ) ( Prednisolone Acetate & Sulfacetamide ) ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIMYCOBACTERIAL ANTIMYCOBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIMYCOBACTERIAL ANTIBACTERIAL ANTIBACTERIAL ANTIVIRAL ANTIBACTERIAL ANTIBACTERIAL ANTIBACTERIAL Approved 1937 Approved 1937 Approved 1939 Approved 1941 Approved 1942 Approved 1946 Approved 1949 Approved 1950 Approved 1950s Approved 1950s Approved 1952 Approved 1953 Approved 1953 Approved 1956 Approved 1958 Approved 1959 Approved 1960 Approved 1960 Approved 1960s Approved 1961 Coly-Mycin S Caprocin Poly-Pred Aureocarmyl Stoxil Flagyl NegGram Neomycin Flumadine Omnipen Neosporin G.U. Clomocycline Versapen-K Fungizone Vibramycin Myambutol Pathocil Cleocin Gentak Floxapen
    [Show full text]
  • Antibacterial Prodrugs to Overcome Bacterial Resistance
    molecules Review Antibacterial Prodrugs to Overcome Bacterial Resistance Buthaina Jubeh , Zeinab Breijyeh and Rafik Karaman * Pharmaceutical Sciences Department, Faculty of Pharmacy, Al-Quds University, Jerusalem P.O. Box 20002, Palestine; [email protected] (B.J.); [email protected] (Z.B.) * Correspondence: [email protected] or rkaraman@staff.alquds.edu Academic Editor: Helen Osborn Received: 10 March 2020; Accepted: 26 March 2020; Published: 28 March 2020 Abstract: Bacterial resistance to present antibiotics is emerging at a high pace that makes the development of new treatments a must. At the same time, the development of novel antibiotics for resistant bacteria is a slow-paced process. Amid the massive need for new drug treatments to combat resistance, time and effort preserving approaches, like the prodrug approach, are most needed. Prodrugs are pharmacologically inactive entities of active drugs that undergo biotransformation before eliciting their pharmacological effects. A prodrug strategy can be used to revive drugs discarded due to a lack of appropriate pharmacokinetic and drug-like properties, or high host toxicity. A special advantage of the use of the prodrug approach in the era of bacterial resistance is targeting resistant bacteria by developing prodrugs that require bacterium-specific enzymes to release the active drug. In this article, we review the up-to-date implementation of prodrugs to develop medications that are active against drug-resistant bacteria. Keywords: prodrugs; biotransformation; targeting; β-lactam antibiotics; β-lactamases; pathogens; resistance 1. Introduction Nowadays, the issue of pathogens resistant to drugs and the urgent need for new compounds that are capable of eradicating these pathogens are well known and understood.
    [Show full text]